Retatrutide and Carbohydrates: What the Research Actually Shows

Quick answer

No published study has manipulated dietary carbohydrate as a variable in retatrutide research. The question arises because retatrutide activates the glucagon receptor, and glucagon drives hepatic glycogenolysis and gluconeogenesis. That is a real mechanistic link — but a mechanism is not evidence that carbohydrate intake changes the compound's effects.

Key takeaways

• No peer-reviewed study has tested retatrutide against varied dietary carbohydrate intake. The question is open, not answered.
• Retatrutide is a 39-amino-acid peptide that activates three receptors: GIP, GLP-1, and glucagon (GCGR).
• Glucagon receptor agonism stimulates hepatic glycogenolysis and gluconeogenesis through cAMP/PKA signalling, which is why carbohydrate handling is mechanistically relevant.
• In the 2023 Phase 2 obesity trial, glycaemic measures improved rather than worsened despite glucagon agonism, because GLP-1 and GIP activity offsets the glucose-raising arm.
• Preclinical rodent work in this class typically uses standardised diets, meaning diet composition is a controlled variable rather than a manipulated one.
• Hepatic glycogen status is a genuine confounder in metabolic studies, and it is under-reported in published methods.
• The glucagon arm of retatrutide is associated with increased energy expenditure and hepatic fat oxidation — processes that are energetically expensive.
• Anyone designing preclinical work with this compound should specify and report diet composition, feeding state at sampling, and time since last feed.

Definitions

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide conjugated to a fatty diacid moiety, engineered to act as a simultaneous agonist at the GIP, GLP-1, and glucagon receptors.¹

Glucagon receptor agonism (GCGR) is activation of the glucagon receptor, a G protein-coupled receptor most abundantly expressed in the liver, which signals through cAMP and PKA to increase hepatic glucose output.²

Glycogenolysis is the breakdown of stored hepatic glycogen into glucose. Gluconeogenesis is the synthesis of new glucose from non-carbohydrate precursors such as amino acids, lactate, and glycerol.

Substrate availability describes the pool of metabolic inputs — glucose, fatty acids, amino acids — accessible to a tissue at a given moment. It varies with feeding state and diet composition, which is why it matters to study design.

Does retatrutide need carbohydrates to work?

No published research has tested this. No peer-reviewed study has compared retatrutide's effects across controlled differences in dietary carbohydrate intake, in humans or in animal models. The claim that retatrutide requires carbohydrates — or works better with them — has no experimental basis at present.

That is the honest state of the literature, and it is worth saying plainly because the question is asked constantly and answered confidently by people who have not looked.

What "no evidence" does and does not mean

It does not mean carbohydrate intake is irrelevant. It means nobody has run the experiment. Those are different statements, and conflating them is how unsupported claims acquire momentum.

There is a genuine mechanistic reason to suspect carbohydrate availability could interact with retatrutide's pharmacology — the glucagon receptor arm, covered in the next section. A plausible mechanism is a reason to design a study. It is not a substitute for having run one.

Why so much confident content exists on this question

Retatrutide sits at the intersection of intense public interest and thin published data. Phase 3 results are not yet available. Into that gap flows a large volume of anecdote, extrapolation from other compounds in the class, and reasoning-by-mechanism presented as finding.

Mechanism-based reasoning is legitimate for generating hypotheses. It fails as evidence because biological systems routinely compensate in ways a pathway diagram does not predict. The Phase 2 glycaemic data, discussed below, is a clean example: the mechanism predicts one thing, the trial reported another.

Why the question exists: the glucagon receptor arm

Retatrutide activates the glucagon receptor alongside GLP-1 and GIP. Glucagon signalling in hepatocytes raises cAMP, activates PKA, and stimulates glycogenolysis and gluconeogenesis while suppressing glycolysis.² This is the direct mechanistic link between the compound and carbohydrate handling, and it is why the question is reasonable to ask.

What glucagon does in the liver

The liver holds the highest density of glucagon receptors in the body; adipose, muscle, pancreas, heart, and gastrointestinal tissue express low or minimal levels.³ When the receptor is activated:

• Glycogenolysis increases — stored hepatic glycogen is broken down to glucose
• Gluconeogenesis increases — new glucose is synthesised from amino acids, lactate, and glycerol
• Glycolysis is suppressed — glucose breakdown is inhibited
• Fatty acid oxidation increases and lipogenesis decreases
• Ureagenesis increases as hepatic amino acid metabolism shifts

The net direction is toward hepatic glucose output. On its own, glucagon agonism raises plasma glucose — which is precisely why decades of drug development treated glucagon as something to block rather than activate.²

The energetic angle

Here is the part that connects glucagon agonism to weight loss rather than to hyperglycaemia. Gluconeogenesis, ureagenesis, and sustained lipolysis are ATP-expensive processes.³ Running them continuously costs energy, and that cost appears to contribute to the increased energy expenditure associated with glucagon receptor agonism in this drug class.

Preclinical work on a long-acting glucagon analogue identified hepatic — not adipose — GCGR as the mediator of weight-loss efficacy, with the effect on energy expenditure dependent on sustained cAMP/PKA signalling.&sup4;

Why this makes people ask about carbs

Follow the chain and the intuition is obvious. Glucagon breaks down glycogen. Glycogen comes from dietary carbohydrate. Therefore carbohydrate intake might determine how much substrate the mechanism has to work with.

The reasoning is not stupid. It is just untested — and, as the next two sections show, it also underestimates how much the other two receptors change the picture.

How the three receptors interact on glucose handling

Retatrutide's three receptor arms pull in different directions on glucose. GLP-1 promotes glucose-dependent insulin secretion and slows gastric emptying. GIP enhances postprandial insulin response. Glucagon raises hepatic glucose output. The net glycaemic effect depends on the balance between them, not on any single arm.

The engineering problem retatrutide solves

Combining glucagon agonism with GLP-1 is not a new idea, and most previous attempts failed. The difficulty is potency balance: enough glucagon activity to capture the energy expenditure benefit, not so much that glycaemic control deteriorates.

Reported relative potencies are informative here. In cell-culture work, retatrutide is less potent than endogenous ligands at the human glucagon and GLP-1 receptors — roughly 0.3 and 0.4 times as active respectively — and substantially more potent at the GIP receptor, by a factor of about 8.9.¹

That asymmetry is the design. The glucagon arm is deliberately restrained relative to the incretin arms.

Why this complicates the carbohydrate question

If glucagon agonism were the dominant signal, dietary carbohydrate would plausibly matter a great deal. But it is the restrained arm in a three-way balance, operating against two incretin signals that push glucose in the opposite direction and simultaneously reduce food intake.

Predicting how dietary carbohydrate composition would move that equilibrium is not something a mechanism diagram can do. It requires measurement.

What the Phase 2 trial actually reported about glycaemia

In the 48-week Phase 2 obesity trial published in the New England Journal of Medicine, retatrutide treatment was associated with improvements in glycaemia, blood pressure, and lipids alongside weight reduction of up to 24.2% at the highest dose.&sup5; Glycaemic measures improved despite glucagon receptor agonism.

This is the single most instructive data point for the carbohydrate question, and it cuts against mechanism-based intuition.

What the trial design was

A phase 2, double-blind, randomised, placebo-controlled trial in adults with obesity, or with a BMI of 27 to under 30 plus at least one weight-related condition. Participants received weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg, or placebo, across 48 weeks. The primary endpoint was percentage change in body weight at 24 weeks.&sup5;

What it did not test

Diet was not a randomised variable. The trial was not designed to compare dietary compositions, and it did not report carbohydrate intake as a stratification factor. Whatever dietary variation existed among participants was uncontrolled background, not a measured exposure.

This is standard for a pharmacological efficacy trial. It also means the trial cannot answer the carbohydrate question in either direction.

The inference that is available

Glycaemic control improved at a population level under conditions where dietary carbohydrate was presumably heterogeneous. That is weak evidence that the compound's glycaemic profile is reasonably robust to ordinary dietary variation — but it is an observation about a mixed population, not a controlled comparison, and it should not be stretched further than that.

A related substudy examined liver fat and MASH biomarkers in participants with metabolic dysfunction-associated steatotic liver disease, again without dietary manipulation as a variable.¹

Why hepatic glycogen status matters in study design

Hepatic glycogen is not merely a glucose reservoir. It participates in regulating gluconeogenesis directly, with preclinical work identifying an AMPK/CRTC2 axis through which glycogen levels influence gluconeogenic gene expression.&sup6; This makes glycogen status a genuine variable in any study of a glucagon-active compound.

The finding that makes this more than bookkeeping

In mouse hepatocytes with reduced glycogen levels, glucagon-driven induction of the gluconeogenic genes Pck1 and G6pc was roughly doubled compared with wild-type, with no change in glucagon receptor expression.&sup6;

Read that carefully. Glycogen status altered the magnitude of the response to glucagon without altering receptor expression. If a comparable relationship holds under pharmacological GCGR agonism, then the glycogen state of the animal at dosing becomes a variable capable of shifting results — independent of dose.

What this means practically for study design

Hepatic glycogen content varies with feeding state, time since last meal, diet composition, and circadian phase. All four are routinely under-specified in published methods sections.

Two studies dosing at the same milligram-per-kilogram level, in the same strain, on the same nominal diet, can differ in hepatic glycogen status if one dosed animals at the start of the dark cycle and the other mid-light cycle. That is a plausible source of between-study variance that is rarely reported and almost never controlled.

This is the practical takeaway for anyone designing work with this compound: record and report feeding state and time since last feed alongside dose. It costs nothing and it is one of the few variables in this space where the mechanistic case for relevance is well documented.

How diet is handled in preclinical metabolic studies

In preclinical metabolic research, diet is typically a controlled constant rather than a manipulated variable. Animals receive standardised chow or a defined high-fat diet, and all groups receive the same formulation. Diet composition establishes the model; it is not usually the intervention being tested.

The standard designs

The fourth row is the design that would answer the carbohydrate question. It is uncommon, because it multiplies group count and cost, and because dietary macronutrient manipulation in rodents introduces its own confounds — palatability differences alter intake, and isocaloric matching across macronutrient ratios is technically demanding.

Why the absence is unsurprising

Pharmaceutical development prioritises establishing whether a compound works and at what dose. Diet-by-compound interaction studies are a later-stage refinement, and retatrutide's development programme has not reached the point where they would be routine.

That explains the gap. It does not fill it.

What a study answering this question would need to look like

A study capable of answering whether dietary carbohydrate modifies retatrutide's effects would require isocaloric diets differing only in carbohydrate proportion, randomised allocation, standardised feeding state at sampling, and direct measurement of hepatic glycogen and energy expenditure alongside the primary metabolic endpoints.

Setting out the requirements is useful for two reasons: it clarifies why the question remains open, and it gives anyone planning work in this area a concrete specification.

Minimum design requirements

Isocaloric diets varying only in carbohydrate fraction. If total energy differs between arms, any result is confounded by energy intake rather than carbohydrate composition. Matching protein while varying the carbohydrate-to-fat ratio is the usual approach.

Randomised allocation with adequate group size. A four-arm design at minimum — two diets × compound and vehicle — with power calculated on the interaction term rather than the main effect. Interaction effects require substantially larger samples than main effects.

Standardised feeding state at sampling. Given the glycogen findings above, fasting duration before sampling should be fixed and reported, and sampling should occur at a consistent circadian point.

Direct measurement rather than inference. Hepatic glycogen content, indirect calorimetry for energy expenditure and substrate oxidation, and hepatic glucose output if the design permits. Body weight alone cannot distinguish the mechanisms in play.

Reported diet composition to the gram. "High-carbohydrate diet" is not a specification. Manufacturer, catalogue number, and full macronutrient breakdown are.

What such a study would resolve

Whether the glucagon arm's contribution to energy expenditure is substrate-limited, and whether the compound's glycaemic profile is stable across carbohydrate intakes. Both are legitimate open questions in the pharmacology of triple agonists, quite apart from the popular version of the question.

Four claims circulating without evidence

Several confident assertions about retatrutide and carbohydrate intake appear widely and are not supported by published research. Each is traceable to a plausible mechanism extended beyond what the data supports.

"Retatrutide requires carbohydrates to work."
No study supports this. The reasoning appears to be that glucagon needs glycogen as substrate — but gluconeogenesis synthesises glucose from amino acids, lactate, and glycerol, which does not require dietary carbohydrate at all.

"Retatrutide works better on a low-carbohydrate diet."
Also untested. This one runs on the opposite intuition — that lower carbohydrate availability pushes the system toward fat oxidation. Plausible, unmeasured.

"Carbohydrate intake determines the energy expenditure effect."
The energy expenditure associated with glucagon agonism appears to derive from the ATP cost of gluconeogenesis, ureagenesis, and sustained lipolysis.³ Whether dietary carbohydrate modulates that cost is unknown.

"Blood sugar effects mean carbs must be restricted."
The Phase 2 trial reported improved glycaemia at the population level.&sup5; Whatever the glucagon arm contributes, the net glycaemic direction under study conditions was favourable.

How to evaluate the next claim you encounter

Ask three questions. Is there a citation? Does the citation actually test the claim, or does it test the mechanism and leave the claim as inference? Was diet a randomised variable in that study, or background?

Most claims in this space fail at the second question.

Handling and documentation for research material

Retatrutide supplied for laboratory research is a lyophilized peptide requiring frozen storage, reconstitution with an appropriate diluent, and lot-specific analytical documentation. Study variables like diet and feeding state are only meaningful if the material itself is characterised.

Why documentation is upstream of everything above

The design considerations in this article assume the compound is what the label says. A vial labelled 10 mg that is 80% peptide by mass delivers 8 mg, and every dose-response conclusion inherits that 20% error.

That distinction — HPLC purity versus net peptide content — is covered in full in our ≥99% purity verification guide, which includes a nine-point audit for evaluating any supplier's Certificate of Analysis.

Practical handling points

• Lyophilized storage: −20 °C or below, sealed, desiccated, protected from light
• Reconstituted storage: 2–8 °C, refrigerated, protected from light; avoid repeated freeze-thaw cycles
• Reconstitution: direct the diluent down the inner vial wall, swirl gently, do not shake
• Concentration: record the reconstitution volume on the vial at the moment you reconstitute — it cannot be recovered later

Our bacteriostatic water to syringe unit conversion chart covers the concentration arithmetic, and the research peptide storage guide covers stability in depth.

Related retatrutide research

References

1. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. PMC11271400
2. Hepatic glucagon action: beyond glucose mobilization. Physiological Reviews. 2024. doi:10.1152/physrev.00028.2023
3. From glucose control to energy expenditure and fat oxidation: the emerging role of glucagon agonism in obesity and MASLD. Journal of Hepatology. 2025;83(6). journal-of-hepatology.eu
4. Glucagon controls obesity-specific energy expenditure via persistent cAMP/PKA signaling. Journal of Hepatology. 2025. journal-of-hepatology.eu
5. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
6. Hepatic glycogen directly regulates gluconeogenesis through an AMPK/CRTC2 axis in mice. PMC12126231
7. Glucagon regulation of energy expenditure. Int J Mol Sci. 2019;20(21):5407. mdpi.com

Methodology. This page reviews published peer-reviewed literature on retatrutide pharmacology and glucagon receptor biology. The central finding — that no published study has manipulated dietary carbohydrate as a variable in retatrutide research — reflects a review of the indexed literature as of the publication date and will be updated if that changes. Mechanistic descriptions are sourced to primary literature and peer-reviewed reviews. Where a claim is inference rather than finding, the page says so explicitly.

Editorial policy. 99 Purity Peptides content is reviewed before publication and updated when new peer-reviewed literature warrants revision. Phase 3 retatrutide trials are ongoing; this page will be revised as results are published. Corrections are logged with the update date.

Research transparency. All material ships with lot-matched analytical documentation, published in our certificate library.

A note on this page. This is an educational overview of published research, not individualized medical or dietary guidance. We encourage you to verify any claim — ours included — against the primary literature. If you have questions about diet alongside any medication, please speak with a qualified healthcare professional.

Research Use Only. Retatrutide referenced on this page is supplied for laboratory research purposes. It is not a drug, food, cosmetic, or medical device, and is not for human or veterinary use. Nothing on this page constitutes medical, dietary, nutritional, or dosing guidance. Retatrutide is an investigational compound that has not received regulatory approval in any jurisdiction.